Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

This prospective cohort study reports aneuploidy score by mFast-SeqS as a strong prognostic marker in MBC patients. mFAST-SeqS is an affordable and easily implementable method for the assessment of total ctDNA levels and, as such, provides an alternative prognostic tool. One mixed cohort (cohort A,...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschoor, Noortje, de Weerd, Vanja, Van, Mai N., Kraan, Jaco, Smid, Marcel, Heijns, Joan B., Drooger, Jan C., Zuetenhorst, Johanna M., van der Padt-Pruijsten, Annemieke, Jager, Agnes, Sleijfer, Stefan, Martens, John W. M., Wilting, Saskia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349058/
https://www.ncbi.nlm.nih.gov/pubmed/37452019
http://dx.doi.org/10.1038/s41523-023-00563-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349058/
https://www.ncbi.nlm.nih.gov/pubmed/37452019
http://dx.doi.org/10.1038/s41523-023-00563-w

Ejemplares similares